title: Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats.
abstract: In the present study, we investigated the effect of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test after the administration of selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor. Single and repeated administration of selegiline significantly decreased the duration of immobility in normal rats. When selegiline was administered for 15 days, we observed a significant decrease in immobility in rats treated with ACTH for 14 days. The immobility-decreasing effect of selegiline was blocked by nafadotride, a selective dopamine D(3)-receptor antagonist in normal and ACTH-treated rats. Selegiline may be useful in an animal model of depressive conditions resistant to tricyclic antidepressant treatment via the dopamine D(3) receptor.
authors.affiliation: Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. ykita@pheasant.pharm.okayama-u.ac.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Kouhei
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Shizue
authors.initials: S
authors.lastname: Kimoto
authors.forename: Hidenori
authors.initials: H
authors.lastname: Sagara
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Shibata
authors.forename: Hiromu
authors.initials: H
authors.lastname: Kawasaki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Sendo
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D001552:Benzazepines / Q000494:pharmacology; D003366:Cosyntropin / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D023421:Models, Animal; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D050637:Receptors, Dopamine D3 / Q000187:drug effects; D012642:Selegiline / Q000494:pharmacology*; D013550:Swimming; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D001552:Benzazepines; D018492:Dopamine Antagonists; D008996:Monoamine Oxidase Inhibitors; D009281:Naphthalenes; D011759:Pyrrolidines; D050637:Receptors, Dopamine D3; D003366:Cosyntropin; D012642:Selegiline; D006220:Haloperidol; C097285:nafadotride